Sunesis Pharmaceuticals (SNSS) Tops Q1 EPS by 3c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q1 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $854 thousand versus the consensus estimate of $980 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c